EWM
PDLI

Elite Wealth Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Elite Wealth Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,500
Closed -$13K – 831
2013
Q4 		$13K Buy
+1,500
New +$12.6K 0.01% 335

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Elite Wealth Management's PDLI Position: Q1 2014 in Review

Elite Wealth Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2014, closing a stake of 1,500 shares — an estimated $13K sold.

Elite Wealth Management first reported a position in PDLI in Q4 2013 and held it in 1 quarter. The position peaked at $13K in Q4 2013. 233 funds tracked by Wall St. Rank hold PDLI as of Q1 2014.

  • Elite Wealth Management reported no remaining PDL BioPharma, Inc. position as of Q1 2014 after selling out during the quarter.
  • Elite Wealth Management sold 1,500 PDL BioPharma, Inc. shares in Q1 2014, an estimated $13K.
  • Elite Wealth Management first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 1 quarter.
  • Elite Wealth Management's PDL BioPharma, Inc. position peaked at $13K in Q4 2013.
  • 233 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2014.

Based on Elite Wealth Management's 13F filing for Q1 2014, filed 23 Nov 2016.